Clearmind Medicine Expands Alcohol Disorder Trial to Israel, Yale, Johns Hopkins

Clearmind Medicine Inc., a clinical-stage biotech company developing psychedelic-derived therapeutics, has expanded its Phase I/IIa clinical trial of CMND-100, a MEAI-based oral medication for Alcohol Use Disorder (AUD), by adding Tel Aviv Sourasky Medical Center (TASMC) in Israel as a new clinical site. This expansion follows the enrollment of the first patient and joins other prestigious institutions such as Yale School of Medicine and Johns Hopkins University School of Medicine, strengthening the trial’s international network. The trial aims to assess the safety, tolerability, pharmacokinetics, and effectiveness of CMND-100 in reducing alcohol cravings and consumption. TASMC’s involvement, under the leadership of Dr. David Zeltser, is expected to facilitate patient recruitment and expedite the trial timeline. Clearmind’s CEO Dr. Adi Zuloff-Shani emphasized the company’s commitment to addressing the global burden of AUD, which causes approximately 2.6 million deaths annually worldwide, through innovative psychedelic-based treatments. The company is also engaging government and political affairs experts to support regulatory acceptance and integration of psychedelic therapies into mainstream healthcare.